Cutaneous Melanoma Rules
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
On the Histological Diagnosis and Prognosis of Malignant Melanoma
J Clin Pathol: first published as 10.1136/jcp.33.2.101 on 1 February 1980. Downloaded from J Clin Pathol 1980, 33: 101-124 On the histological diagnosis and prognosis of malignant melanoma ARNOLD LEVENE Hunterian Professor, Royal College of Surgeons, and Department of Histopathology, The Royal Marsden Hospital, Fulham Road, London SW3, UK SUMMARY This review deals with difficulties of diagnosis in cutaneous malignant melanoma encountered by histopathologists of variable seniority and is based on referred material at The Royal Marsden Hospital over a 20-year period and on the experience of more than two-and-a-half thousand cases referred to The World Health Organisation Melanoma Unit which I reviewed when chairman of the Pathologists' Committee. Though there is reference to the differential diagnosis of primary and metastatic tumour, the main concern is with establishing the diagnosis of primary melanoma to the exclusion of all other lesions. An appendix on recommended diagnostic methods in cutaneous melanomas is included. Among the difficult diagnostic fields in histopathol- not to be labelled malignant because it 'looks nasty'. ogy melanocytic tumours have achieved a notoriety. Thus, until the critical evaluation of the 'malignant Accurate diagnosis, however, is of major clinical melanoma of childhood' by Spitz (1948) the naevus importance for the following reasons: with which this investigator's name is associated was 1 The management of the primary lesion is reckoned among the malignancies on histological principally by surgical excision with a large margin grounds. of normal appearing skin. The consequences of over-diagnosis are those of major disfiguring surgery Naevus and melanoma cells http://jcp.bmj.com/ and its morbidity. -
What Are Basal and Squamous Cell Skin Cancers?
cancer.org | 1.800.227.2345 About Basal and Squamous Cell Skin Cancer Overview If you have been diagnosed with basal or squamous cell skin cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Basal and Squamous Cell Skin Cancers? Research and Statistics See the latest estimates for new cases of basal and squamous cell skin cancer and deaths in the US and what research is currently being done. ● Key Statistics for Basal and Squamous Cell Skin Cancers ● What’s New in Basal and Squamous Cell Skin Cancer Research? What Are Basal and Squamous Cell Skin Cancers? Basal and squamous cell skin cancers are the most common types of skin cancer. They start in the top layer of skin (the epidermis), and are often related to sun exposure. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer cells. To learn more about cancer and how it starts and spreads, see What Is Cancer?1 Where do skin cancers start? Most skin cancers start in the top layer of skin, called the epidermis. There are 3 main types of cells in this layer: ● Squamous cells: These are flat cells in the upper (outer) part of the epidermis, which are constantly shed as new ones form. When these cells grow out of control, they can develop into squamous cell skin cancer (also called squamous cell carcinoma). -
Thrombotic Thrombocytopenic Purpura Due to Checkpoint Inhibitors
Hindawi Case Reports in Hematology Volume 2018, Article ID 2464619, 4 pages https://doi.org/10.1155/2018/2464619 Case Report Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors Alexey Youssef,1 Nawara Kasso,2 Antonio Sergio Torloni,3 Michael Stanek,4 Tomislav Dragovich,5 Mark Gimbel,6 and Fade Mahmoud 6 1Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK 2Faculty of Medicine, Tishreen University, Lattakia, Syria 3Medical Director, Stem Cell )erapy, Apheresis, and Transfusion Medicine, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 4Division of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 5Chief, Division of Medical Oncology and Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA 6)e T.W. Lewis Melanoma Center of Excellence, Banner MD Anderson Cancer Center, Gilbert, AZ, USA Correspondence should be addressed to Fade Mahmoud; [email protected] Received 16 September 2018; Revised 23 November 2018; Accepted 28 November 2018; Published 20 December 2018 Academic Editor: Akimichi Ohsaka Copyright © 2018 Alexey Youssef et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ipilimumab is a monoclonal antibody that enhances the efficacy of the immune system by targeting a cytotoxic T-lymphocyte- associated protein 4 (CTLA-4), which is a protein receptor that downregulates the immune system. Nivolumab is also a hu- manized monoclonal antibody that targets another protein receptor that prevents activated T cells from attacking the cancer; this receptor is called programmed cell death 1 (PD-1). -
Lumps & Bumps: Approach to Common Dermatologic Neoplasms
Case-Based Approach to Common Dermatologic Neoplasms Patrick Retterbush, MD, FAAD Mohs Surgery & Dermatologic Oncology Associate Member of the American College of Mohs Surgery Private Practice: Lockman Dermatology January 27th 2018 Disclosure of Relevant Financial Relationships • I do not have any relevant financial relationships, commercial interests, and/or conflicts of interest regarding the content of this presentation. Goals/Objectives • Recognize common benign growths • Recognize common malignant growths • Useful clues & examination for evaluating melanocytic nevi and when to be concerned for melanoma/atypical moles • How to perform a basic skin biopsy and which method/type to choose • Basic treatment/when to refer Key Questions & Physical Examination Findings for a Growth History Physical Examination • How long has the lesion been • Describing a growth present? – flat or raised? • flat – macule (<1cm) or patch (>1cm) – years, months, weeks • raised – papule (<1cm) or plaque (>1cm) – nodule if deep (majority of lesion in • Has it changed? dermis/SQ) – Size – secondary descriptive features • scaly (hyperkeratosis, retention of strateum – Shape corneum) – Color • crusty (dried serum, blood, or pus on surface) • eroded or ulcerated (partial vs. full thickness – Symptoms – pain, bleeding, itch? epidermal loss) – Over what time frame? • color (skin colored, red, pigmented, pearly) • feel (hard or soft, mobile or fixed) • PMH: • size: i.e. 6 x 4mm – prior skin cancers • Look at the rest of the skin/region of skin • SCC/BCCs vs. melanoma -
An Uncommon but Often Lethal Skin Cancer Could Be That Individual Melanoma Patients Cancers Can Be Assessed by Gene Expression to Answer These Questions
HEALTH in the US and Australia are successfully actions of vitamin D, genetic alterations CONCLUSION treated by early surgery. However, 10 in the gene that controls the vitamin D At this point, the role of genetics in percent of melanomas have been highly receptor or related genes might reasonably melanoma is still unclear. While intense, recalcitrant to treatment. In the quest for be associated with poorer survival from intermittent sun exposure is clearly better understanding, multiple investiga- melanoma. It may be that individuals who important in the etiology of melanoma, tors are evaluating the role of genetic factors have aggressive melanoma have a different its importance for survival is not known. in survival. While excessive, intermittent set of genetic mutations from those com- Therefore, one cannot reliably say whether sun exposure is an important risk factor mon in more indolent melanomas. nature or nurture (i.e., behavior) is more Merkel Cell Carcinoma: for melanoma, it does not appear to be as- The genetic factors associated with important in either the etiology or the sociated with poorer melanoma survival. melanoma progression and survival are progression of melanoma. Hopefully, this Thus, genetic factors may be the culprit; it still being explored. While genetics in other uncertainty will continue to spur research An Uncommon But Often Lethal Skin Cancer could be that individual melanoma patients cancers can be assessed by gene expression to answer these questions. JAYASRI IYER, MD, AND PAUL NGHIEM, MD, PHD with a particular constellation of inherited analyses from fresh tumor tissue, this is ex- genetic mutations are those who have tremely difficult in melanoma, as primary DR. -
A Brighter Future for Psoriasis Patients Melanoma and Skin Cancer Center
Skin Health FROM THE MOUNT SINAI DEPARTMENT OF DERMATOLOGY FALL 2013 MESSAGE FROM THE CHAIR A Brighter Future for Psoriasis Patients By Mark G. Lebwohl, MD, Sol and Clara Kest Professor and Chair ount Sinai has been at the forefront of psoriasis research since Mthe 1980’s, when we introduced a topical combination regimen that remains the standard of care around the world even today. This consists of both a superpotent corticosteroid and a vitamin-D analog such as calcipotriene (Dovonex®) or calcitriol (Vectical®). The use of combination therapy led to the invention of Taclonex®, a popular and effective psoriasis formula that contains two topical agents. While refining the concept of combination therapy, we discovered that some topical preparations inactivate others, and subsequently we fostered the understanding that two or more ingredients, when applied together, must be shown to be compatible. In recent years this rule has been Dr. Mark G. Lebwohl embraced for all topical medicines, not just for psoriasis drugs. continued on page 4 BREAKING NEWS In This Issue Melanoma and Skin Cancer Center By Philip Friedlander, MD, PhD LASER HAIR REMOVAL Alan Kling, MD Page 2 he Tisch Cancer Institute is pleased to announce the creation of the Melanoma and TSkin Cancer Center, a virtual gathering place designed to provide a full array of medical LOOKING FAB THIS FALL resources to skin cancer patients. As part of its mission to deliver the highest quality of care, David S. Orentreich, MD the Center has assembled a team of leading specialists representing the fields of dermatology, Marina I. Peredo, MD medical oncology, surgery, dermatopathology, podiatry, and social work. -
Merkel Cell Carcinoma: Update and Review Timothy S
Merkel Cell Carcinoma: Update and Review Timothy S. Wang, MD,* Patrick J. Byrne, MD, FACS,† Lisa K. Jacobs, MD,‡ and Janis M. Taube, MD§ Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal cutaneous malignancy that is not usually suspected at the time of biopsy. Because of its increasing incidence and the discovery of a possible viral association, interest in MCC has escalated. Recent effort has broadened our breadth of knowledge regarding MCC and developed instruments to improve data collection and future study. This article provides an update on current thinking about the Merkel cell and MCC. Semin Cutan Med Surg 30:48-56 © 2011 Elsevier Inc. All rights reserved. erkel cell carcinoma (MCC) is a rare, aggressive, and current thinking, including novel insights into the Merkel Moften fatal cutaneous malignancy. It usually presents as cell; a review of the 2010 National Comprehensive Cancer a banal-appearing lesion and the diagnosis is rarely suspected Network (NCCN) therapeutic guidelines and new American at the time of biopsy. Because of increasing incidence and the Joint Committee on Cancer (AJCC) staging system; recom- discovery of a possible viral association, interest in MCC has mendations for pathologic reporting and new diagnostic escalated rapidly. codes; and the recently described Merkel cell polyoma virus From 1986 to 2001, the incidence of MCC in the United (MCPyV). States has tripled, and approximately 1500 new cases are diagnosed each year.1,2 MCC occurs most frequently among elderly white patients and perhaps slightly more commonly History in men. MCCs tend to occur on sun-exposed areas, with Merkel cells (MCs) were first described by Friedrich Merkel 3 nearly 80% presenting on the head, neck, and extremities. -
Lentigo Maligna Melanoma and Simulants Maui January 2020 Superficial Atypical Melanocytic Proliferations
Superficial Atypical Melanocytic Proliferations II. Lentigo Maligna Melanoma and Simulants Maui January 2020 Superficial Atypical Melanocytic Proliferations • RGP Melanomas • SSM, LMM, ALM, MLM • Intermediate lesions • Dysplastic nevi, Atypical lentiginous proliferations in high CSD skin; Atypical Acral lentiginous nevi • Superficial atypical melanocytic proliferations • Pagetoid plaque-like Spitz nevi; pigmented spindle cell nevus (Reed) • Special site nevi (genital, breast, scalp, ear, flexural, etc). • Superficial atypical melanocytic proliferations of uncertain significance • Atypical/unusual/uncertain examples of all of the above Superficial Atypical Melanocytic Proliferations • RGP Melanomas • SSM, LMM, ALM, MLM • Intermediate lesions • Dysplastic nevi, Atypical lentiginous proliferations in high CSD skin; Atypical Acral lentiginous nevi • Superficial atypical melanocytic proliferations • Pagetoid plaque-like Spitz nevi; pigmented spindle cell nevus (Reed) • Special site nevi (genital, breast, scalp, ear, flexural, etc). • Superficial atypical melanocytic proliferations of uncertain significance • Atypical/unusual/uncertain examples of all of the above High CSD Melanomas and Simulants. D Elder, Maui, HI Jan 2020 Lentigo maligna melanoma Atypical lentiginous nevi/proliferations High CSD: Lentiginous Nevi and Lentigo Maligna Melanoma and Simulant(s) • Lentiginous Melanoma of Sun-Damaged Skin • LMM in situ • LMM invasive • Distinction from Dysplastic Nevi (Dysplastic Nevus-like Melanoma/Nevoid Lentigo Maligna • Lentiginous Nevi of -
Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: an Ancient Drug Revisited
LETTER TO THE EDITOR DOI: 10.4274/jtad.galenos.2020.13007 J Turk Acad Dermatol 2020;14(3):93-94 Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited Gökhan Okan1, Kezban Nur Pilancı2, Cuyan Demirkesen3 1Private Dermatologist, Istanbul, Turkey 2Memorial Bahcelievler Hospital, Clinic of Oncology, Istanbul, Turkey 3Acibadem University Faculty of Medicine, Department of Pathology, Istanbul, Turkey Keywords: Checkpoint inhibitors, Nivolumab, Psoriasis, Melanoma, Sulfasalazine Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. We report de novo development of psoriasis vulgaris in a patient receiving nivolumab for treatment of metastatic melanoma which was controlled with sulfasalazine (SSZ). A 69-year-old male was initiated with nivolumab 3 mg/kg every two weeks for metastatic BRAF-negative melanoma of the back. The patient’s medical history was notable for arterial hypertension and dyslipidemia for which he has been medically treated. There was no personal or family history of psoriasis. One week after the fourth cycle of nivolumab, asymptomatic, sharply bordered, erythematous and scaly plaques were seen on the the anterolateral aspects of shins, dorsa of hands, feet, scalp, and trunk (Figure 1a). A skin biopsy revealed psoriasiform epidermal hyperplasia with prominent orthohyperkeratosis, and mounds of parakeratosis, containing neutrophils. The suprapapillary epidermis was thinned, and there were collections of neutrophils in the spinous layers which were consistent with psoriasis (Figure 1b, 1c). The patient had psoriasis area and severity index score of 12. He did not have psoriatic arthritis. The patient’s melanoma improved with nivolumab therapy but the skin lesions increased. -
MAGE-A Expression in Oral and Laryngeal Leukoplakia Predicts Malignant Transformation
Modern Pathology (2019) 32:1068–1081 https://doi.org/10.1038/s41379-019-0253-5 ARTICLE MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation 1 2 1 1 1 5 Christoph A. Baran ● Abbas Agaimy ● Falk Wehrhan ● Manuel Weber ● Verena Hille ● Kathrin Brunner ● 3 3 4 1 1 Claudia Wickenhauser ● Udo Siebolts ● Emeka Nkenke ● Marco Kesting ● Jutta Ries Received: 15 October 2018 / Revised: 17 February 2019 / Accepted: 27 February 2019 / Published online: 1 April 2019 © United States & Canadian Academy of Pathology 2019 Abstract Leukoplakia is a potential precursor of oral as well as laryngeal squamous cell carcinoma. Risk assessment of malignant transformation based on the grade of dysplasia of leukoplakia often does not lead to reliable results. However, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, and leukoplakia express single or multiple members of the melanoma- associated antigens A (MAGE-A) family, while MAGE-A are absent in healthy mucosal tissue. The present study aimed at determining if there is an association between the expression of MAGE-A in leukoplakia and malignant transformation to oral or laryngeal squamous cell carcinoma. Paraffin-embedded tissues of 205 oral and laryngeal leukoplakia, 90 1234567890();,: 1234567890();,: corresponding tumors, and 40 healthy oral mucosal samples were included in the study. The grade of dysplasia of the leukoplakia samples was determined histopathologically. The leukoplakia samples were divided into lesions that transformed to oral and laryngeal squamous cell carcinoma (n = 91) and lesions that did not (n = 114) during a 5 years follow-up. The expression of MAGE-A3/6 and MAGE-A4 was analyzed by real-time RT-PCR. -
Actinic Keratosis
ACTINIC KERATOSIS http://www.aocd.org An actinic keratosis is a scaly or crusty bump that forms on the skin surface. They are also called solar keratosis, sun spots, or precancerous spots. Dermatologists call them "AK's" for short. They range in size from as small as a pinhead to over an inch across. They may be light or dark, tan, pink, red, a combination of these, or the same color as ones skin. The scale or crust is horn-like, dry, and rough, and is often recognized easier by touch rather than sight. Occasionally they itch or produce a pricking or tender sensation, especially after being in the sun. They may disappear only to reappear later. Half of the keratosis will go away on their own if one avoid all sun for a few years. One often sees several actinic keratoses show up at the same time. Keratoses are most likely to appear on sun exposed areas: face, ears, bald scalp, neck, backs of hands and forearms, and lips. They may be flat or raised on appearance. Why is it dangerous? Actinic keratosis can be the first step in the development of skin cancer, and, therefore, is a precursor of cancer or a precancer. It is estimated that 10 to 15 percent of active lesions, which are redder and more tender than the rest will take the next step and progress to squamous cell carcinomas. These cancers are usually not life threatening, provided they are detected and treated in the early stages. However, if this is not done, they can bleed, ulcerate, become infected, or grow large and invade the surrounding tissues and, 3% of the time, will metastasize or spread to the internal organs. -
Second Revised Proposed Regulation of the State
SECOND REVISED PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 February 5, 2018 EXPLANATION – Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY: §§1, 2, 4-9 and 11-15, NRS 457.065 and 457.240; §3, NRS 457.065 and 457.250; §10, NRS 457.065; §16, NRS 439.150, 457.065, 457.250 and 457.260. A REGULATION relating to cancer; revising provisions relating to certain publications adopted by reference by the State Board of Health; revising provisions governing the system for reporting information on cancer and other neoplasms established and maintained by the Chief Medical Officer; establishing the amount and the procedure for the imposition of certain administrative penalties by the Division of Public and Behavioral Health of the Department of Health and Human Services; and providing other matters properly relating thereto. Legislative Counsel’s Digest: Existing law defines the term “cancer” to mean “all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma and leukemia” and, before the 78th Legislative Session, required the reporting of incidences of cancer. (NRS 457.020, 457.230) Pursuant to Assembly Bill No. 42 of the 78th Legislative Session, the State Board of Health is: (1) authorized to require the reporting of incidences of neoplasms other than cancer, in addition to incidences of cancer, to the system for reporting such information established and maintained by the Chief Medical Officer; and (2) required to establish an administrative penalty to impose against any person who violates certain provisions which govern the abstracting of records of a health care facility relating to the neoplasms the Board requires to be reported.